Tybriva Capsule

Introduction

Tybriva is a prescription medication that contains the active ingredient Ibrutinib. It is also known by its generic name, Ibrutinib. Tybriva is primarily used for the treatment of certain types of cancer.

Uses

Tybriva is prescribed to patients with specific types of cancer, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM). It is used when other treatments have not been effective or have stopped working.

Dosage and Administration

The dosage of Tybriva may vary depending on the type of cancer being treated and the patient’s individual factors. Follow the instructions provided by your healthcare professional. Typically, the recommended dose is taken orally once a day with a full glass of water. Swallow the capsule whole and not to open, crush, or chew it.

Mechanism of Action

Tybriva belongs to a class of medications called Bruton’s tyrosine kinase (BTK) inhibitors. It works by blocking the action of BTK, an enzyme that is involved in the growth and survival of cancer cells. By inhibiting BTK, Tybriva helps to slow down the growth and spread of cancer cells in the body.

Side Effects

Common side effects may include diarrhea, nausea, fatigue, muscle or joint pain, and rash. These side effects are usually mild and temporary. However, if they become severe or persist. Inform your healthcare professional.

Serious side effects of Tybriva may include bleeding, infections, irregular heartbeat, shortness of breath, severe skin reactions, and high blood pressure. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Tybriva may interact with other medications. Inform your healthcare professional about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Some medications, such as strong CYP3A inhibitors or inducers, may affect the way Tybriva works or increase the risk of side effects. Your healthcare professional will assess any potential drug interactions and adjust your medication regimen accordingly.

Precautions

Before starting Tybriva, discuss your medical history and any underlying conditions with your healthcare professional. Tybriva may not be suitable for everyone, especially those with a history of bleeding disorders, heart problems, or liver problems. Avoid grapefruit or grapefruit juice while taking Tybriva, as it may increase the risk of side effects.

Storage

Tybriva should be stored at room temperature, away from moisture and heat. Keep the medication in its original container and make sure it is tightly closed when not in use. Do not store Tybriva in the bathroom or any area with high humidity. Keep it out of reach of children and pets.

Patient Tips

• Take Tybriva exactly as prescribed by your healthcare professional.
• Do not stop taking the medication without consulting your healthcare professional, even if you start to feel better.
• If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• If you have any questions or concerns about Tybriva, reach out to your healthcare professional for clarification.
• attend regular follow-up appointments with your healthcare professional to monitor the effectiveness and safety of Tybriva.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Imbruvica 140 mg Film-Coated Tablets (Health Professionals SmPC) Available at:
• Ibrutinib (Drugs.com) [Accessed 7 Jun. 2024] (online) Available at:
• ibrutinib 70 mg/ml oral suspension (RX) [Accessed 18 Jun. 2024] (online) Available at:
• Advances in Leukemia Research (National Cancer Institute) [Accessed 2 Jun. 2024] (online) Available at:
• Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10. [Accessed 9 Jun. 2024] Available at: